Results 1 to 10 of about 1,999 (119)

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study [PDF]

Therapeutic Advances in Neurological Disorders
Background: Siponimod is approved in Europe for active secondary progressive multiple sclerosis (SPMS), but real-world data on its treatment patterns and outcomes in people with SPMS (pwSPMS) is limited.
Celia Oreja-Guevara, Irene Gómez-Estévez, Laura Agüado García, Jesus Martín Martínez, Montserrat Gómez Gutiérrez, Francisco Gascón Giménez, Eduardo Agüera Morales, Virginia Meca-Lallana, Francisco Javier Barrero Hernández, Vicente González Quintanilla, Lucía Romero Pinel, Virginia Delgado Gil, Eduardo Durán Ferreras, Rosario Blasco Quílez, Jose Meca-Lallana, Lamberto Landete Pascual, Yolanda Aladro-Benito, Sabas Boyero Durán, Julia Gracia Gil, Ana Belén Caminero Rodríguez, Antonio Tomás Cano Orgaz, Sara Eichau Madueño, María Rosa Querol Pascual, María Otano Martínez, Ana María Alonso Torres, Carmen Calles Hernández, Ana López Real, Adrián Ares Luque, Jose Ramón Lorenzo González, Lidia Gómez Vicente, María Díaz Sánchez   +30 more
doaj   +2 more sources

A real-world retrospective study to assess the effectiveness and safety profile of siponimod in Chinese patients with relapsing forms of multiple sclerosis [PDF]

BMC Neurology
Background Based on its favourable benefit–risk profile in clinical trials, siponimod was approved in China in 2020 for relapsing forms of multiple sclerosis (RMS). We evaluated its real-world (RW) effectiveness and safety profile in patients with RMS in
Yao Zhang, Hongbo Liu, Zheng Li, Ming Zhou, Min Cai, Lyra Liu, Anne Lin, Yan Xu   +7 more
doaj   +2 more sources

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study. [PDF]

Eur J Neurol
Siponimod lowered the risk of wheelchair use in SPMS patients compared to placebo, especially in those with active disease. Time to wheelchair is a key metric for evaluating treatment in SPMS. ABSTRACT Background Delaying time to requiring a wheelchair in people living with MS is an important treatment goal to maintain quality of life and guard against
Vermersch P, Arnould S, Gold R, Kappos L, Fox R, Bar-Or A, Cree BAC, Ansari S, Meier DP, Karlsson G, Rouyrre N, Giovannoni G.   +11 more
europepmc   +2 more sources

Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice [PDF]

Therapeutic Advances in Neurological Disorders
Background: Siponimod, a selective sphingosine-1-phosphate receptor modulator was approved for patients with Secondary progressive Multiple Sclerosis (SPMS) with ongoing disease activity.
Aurora Zanghì, Giovanna Borriello, Matteo Foschi, Assunta Bianco, Elisabetta Signoriello, Maria Cellerino, Paola Sofia Di Filippo, Francesco Baldisseri, Giuseppe Romano, Alessandra Cicia, Giacomo Lus, Matilde Inglese, Massimiliano Mirabella, Carlo Avolio, Emanuele D’Amico   +14 more
doaj   +2 more sources

Siponimod inhibits disease-associated microglia-T cell interactions in chronic experimental autoimmune encephalomyelitis [PDF]

Acta Neuropathologica Communications
Chronically inflamed, reactive microglia represent a prominent feature of secondary progressive multiple sclerosis (SPMS). Especially their interplay with encephalitogenic T cells promotes neuroaxonal damage associated with disease progression.
Leila Husseini, Anastasia Geladaris, Marlene C. J. Steinleitner, Darius Häusler, Martin S. Weber   +4 more
doaj   +2 more sources

Does Siponimod Exert Direct Effects in the Central Nervous System?

Cells, 2020
The modulation of the sphingosine 1-phosphate receptor is an approved treatment for relapsing multiple sclerosis because of its anti-inflammatory effect of retaining lymphocytes in lymph nodes.
Markus Kipp
exaly   +3 more sources

Extracellular Vesicle-Associated miRNA in Multiple Sclerosis Subtypes: Differential Profiles in Secondary Progressive Disease and the Effect of One-Year Siponimod Treatment [PDF]

Cells
Circulating extracellular vesicle-associated microRNAs (EV-miRNAs) are emerging as promising peripheral biomarkers in multiple sclerosis (MS). This prospective, observational pilot study was conceived as a hypothesis-generating investigation to ...
Oana Vrînceanu, Smaranda Maier, Doina Manu, Claudia Bănescu, Rodica Bălașa   +4 more
doaj   +2 more sources

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod

Clinical and Translational Science
Multiple sclerosis (MS) is a significant cause of neurological disability in young adults. Siponimod, a potent sphingosine‐1‐phosphate (S1P) receptor modulator, is used to treat MS by reducing T‐cell recirculation and central inflammation.
Felix Huth, Kasra Shakeri‐Nejad, Anne Gardin, Bharti Shah, Oliver Pohl, Nicole Pezous, Thomas Faller   +6 more
doaj   +2 more sources

Engineered ETS1-Nanoconjugate Restores Immune Homeostasis through Dual Immune-Vascular Modulation in Relapsing and Progressive Multiple Sclerosis. [PDF]

Adv Healthc Mater
The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Zhang F, Yang SB, Luo Y, Sun XD, Chang BH, Zhou DQ, Jiang JJ, Li YN, Wu JH, Jin HJ, Yang H, Hu H, Zhou YF, Hu B.   +13 more
europepmc   +2 more sources

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross-sectional analysis. [PDF]

Br J Clin Pharmacol
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Narlawar P, Ratcliffe C, Sharma V, Newman WG, Pirmohamed M, McDermott J.   +5 more
europepmc   +2 more sources